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48 vs. 19 6 2; Ap5A, 227 6 35 vs. 10 6 1; Ap6A, 141 6 45 vs.Increased vascular growth in hemodialysis patients induced by
4 6 1; each P , 0.01].platelet-derived diadenosine polyphosphates.
Conclusions. The increased amount of dinucleoside poly-Background. Enhanced vascular smooth muscle cell (VSMC)
phosphate in platelets from hemodialysis patients may be angrowth is one hallmark of atherosclerosis. One mechanism
important additional atherogenic factor.responsible for stimulating arterial smooth muscle cell growth
is the release of growth factors from platelets aggregating at
endothelial lesions. Since in end-stage renal failure (ESRF)
atherogenesis is markedly accelerated, the release of VSMC Premature atherosclerosis is one of the most important
growth factors on aggregation of platelets from hemodialysis
causes of death in end-stage renal failure patients [1, 2].patients, ESRF patients in the predialysis stage, and healthy
Several explanations of premature atherosclerosis havesubjects was examined.
Methods. Platelets were activated by thrombin, and the su- been proposed in these patients, including hypertriglyc-
pernatant was tested for growth stimulation in VSMCs from rat eridemia, increased lipoprotein (a) levels, increased pro-
aorta. The cell proliferation rate was determined by [3H]-thymi- duction of oxidized low-density lipoproteins, hyperten-
dine incorporation in VSMCs. The diadenosine polyphosphate sion, and hyperhomocysteinemia [3].(ApnA with N 5 3 to 6) content in the supernatant and in In addition to these known atherogenic mechanisms,intact platelets was determined using a chromatographic assay
still other unknown factors may contribute to the mark-established on the basis of affinity- and reversed-phase chro-
edly increased atherogenic potential in hemodialysis pa-matographic methods.
Results. The thrombin-activated platelet supernatant from tients. One important atherogenic mechanism is based
hemodialysis patients (N 5 15) increased the [3H]-thymidine on the interaction of platelets with defective endothe-
incorporation rate in VSMCs in comparison to the supernatant lium. At the site of endothelial lesions, platelet adhesion
of healthy control subjects (N 5 17, counts/supernatant of 106
and aggregation occurs, and hence, growth factors andstimulated platelets 6 SEM, 604 6 71 vs. 364 6 45, P , 0.05).
cytokines are released from platelets. Consequently, vas-The addition of the selective P2-receptor blocker pyridoxal-
phosphate-6-azophenyl-2,4-disulfonic acid to supernatants inhib- cular smooth muscle cell (VSMC) growth is induced,
ited the stimulatory effects of ApnA on the growth of vascular which is one of the principal processes found in athero-
smooth muscle cells (219 6 53 vs. 156 6 71 counts/supernatant sclerotic vascular lesions.
of 106 stimulated platelets 6 SEM). The ApnA (N 5 3 to 6) In this study, we examined the effect of platelet aggre-amount of thrombin-activated platelet supernatants from he-
gation in hemodialysis patients on VSMC growth. Diade-modialysis patients was significantly higher than in platelets
nosine polyphosphates (ApnA; N 5 3 to 6), which arefrom 10 healthy control subjects (Ap3A, 119 6 32 vs. 12 6 3;
Ap4A, 154 6 59 vs. 43 6 20; Ap5A, 39 6 14 vs. 13 6 6; Ap6A, known as cellular growth factors [4], appear to play an
42 6 19 vs. 2 6 1 fg/platelet 6 SEM, each P , 0.05, N 5 10). important role in the enhanced VSMC growth stimula-
The intracellular ApnA (N 5 3 to 6) amount of intact platelets tion by platelet supernatants in end-stage renal failure.
from hemodialysis patients (N 5 61) was significantly higher
than that from healthy control subjects [N 5 30, ApnA amount
(fg/platelet 6 SEM): Ap3A, 366 6 68 vs. 14.7 6 1; Ap4A, 336 6 METHODS
High-performance liquid chromatography (HPLC) wa-
ter (gradient grade), adenosine-59-triphosphate (ATP),Key words: human platelets, end-stage renal disease, vascular smooth
muscle cells, atherosclerosis, endothelium, cellular growth factor. adenosine-59-tetraphosphate, 1-ethyl-3-(3-dimethylami-
nopropyl)carbodiimide, and (N-[2-hydroxyethyl]pipera-Received for publication December 4, 1999
zine-N9-[2-ethanesulfonic acid]) were from Sigma (Dei-and in revised form September 18, 2000
Accepted for publication September 22, 2000 senhofen, Germany). Diadenosine octaphosphate (Ap8A)
was synthesized according to Ng and Orgel [5] and puri-Ó 2001 by the International Society of Nephrology
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Table 1. Clinical and biochemical characteristics of hemodialysis patients, end-stage renal failure patients in the predialysis stage and
healthy control subjects
End-stage renal failure
Hemodialysis patients in the Healthy control
patients predialysis stage subjects
N561 N55 N530 P value
Age years 6262 6462 5863 NS
Gender m/f 30/31 3/2 16/14
Body mass index kg/m2 24.560.6 25.261.7 25.060.7 NS
Heart rate min21 7761 7763 7461 NS
Blood pressure mm Hg
Systolic 14763 15866 12862 ,0.01
Diastolic 7661 7966 8061 NS
Blood urea nitrogen mg/dL 6963 7065 7.560.5 ,0.001
Serum creatinine mg/dL 9.460.3 8.660.6 0.960.0 ,0.001
Platelet count 109/L 254611 168654 200610 ,0.05
Values are mean 6 SEM. P values indicate comparisons between hemodialysis patients and healthy control subjects. NS is not significant.
fied by a method described by Jankowski et al [6]. All obtained or if Doppler sonography of the carotid arteries
revealed carotid artery stenosis. Peripheral arterial oc-other substances were purchased from Merck (Darm-
stadt, Germany) if not indicated otherwise. clusive disease was diagnosed if patients reported a his-
tory of intermittent claudication or if Doppler sonogra-
Subjects phy revealed peripheral arterial stenosis.
Clinical and biochemical characteristics of hemodialy-
Isolation of human plateletssis patients, end-stage renal failure patients in the predial-
ysis stage, and control subjects. After giving informed To obtain human platelets for activation by thrombin,
20 mL of heparinized blood from hemodialysis patients,consent, 30 healthy control subjects with normal renal
function, 5 patients with chronic renal failure, and 61 end-stage renal failure patients in the predialysis stage,
and healthy control subjects were centrifuged at 160 3 ghemodialysis patients who had been undergoing mainte-
nance hemodialysis for 22 6 6 months (mean 6 SEM) for 10 minutes.
The resulting platelet-rich plasma was diluted 7:1 withwere enrolled in this study. Blood samples were drawn
immediately before the hemodialysis session. The clini- a solution containing 75 mmol/L trisodium citrate, 41
mmol/L citric acid, and 136 mmol/L glucose. The plateletcal and biochemical characteristics of hemodialysis pa-
tients, end-stage renal failure patients in the predialysis pellet obtained by centrifugation at 240 3 g for 15 min-
utes was resuspended in a solution containing 135 mmol/Lstage, and healthy control subjects are given in Table 1.
Healthy control subjects did not use platelet inhibitors. NaCl, 2.6 mmol/L KCl, 10 mmol/L NaHCO3, 6 mmol/L
glucose, 1.2 mmol/L HEPES, and 0.35% albumin, indicat-The cause of end-stage renal failure was chronic intersti-
tial nephritis in 12, chronic glomerulonephritis in 19, ing that contact activation of the platelets was minimal
because of the careful centrifugation procedure. The resus-diabetic nephropathy in 25, and polycystic kidney disease
in 5 patients. All received hemodialysis three times a pended platelets were incubated with thrombin (0.05 U/mL)
for one minute. The supernatant was removed from theweek. As confirmed by the clinical examination and rou-
tine laboratory examination, patients were in a good state platelets by centrifugation (2500 3 g at 48C for 10 min)
and was used for cell proliferation assay and for chroma-of health. All patients were stable and free from inter-
current illness. The dialysates used were bicarbonate tography. Ap8A was added to the sample of the chroma-
tography as an internal standard.based. Kt/V values (the amount of plasma cleared of urea
divided by the urea distribution volume) were measured For the quantitation of the intracellular amount of
ApnA in intact human platelets, a 4 mL blood sampleaccording to this formula: Kt/V 5 2ln(R 2 0.03) 1 (4 2
3.5 3 R) 3 UF/W, where R is the post/preplasma urea per donor was drawn from the hemodialysis patients,
the end-stage renal failure patients in the predialysisnitrogen ration, UF is the ultrafiltrate volume (liters)
removed, and W is the postdialysis weight (kg). stage, and healthy control subjects. The biochemical
characteristics are given in Table 1. The blood was centri-Furthermore, the hemodialysis patients were assessed
with respect to cardiovascular disorders. Cardiovascular fuged at 200 g for 10 minutes to obtain platelet-rich
plasma, which was again centrifuged at 2500 3 g for fivedisease was assumed if a history of myocardial infarction
has been obtained or if exercise testing or coronary angi- minutes. The sedimented platelets were washed twice
with a physiological NaCl solution and centrifuged atography revealed pathologic findings. Cerebrovascular
disease was diagnosed if a history of stroke had been 2500 3 g for five minutes. After removal of the physio-
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logical NaCl solution, the platelet pellet was frozen at 48-hour incubation period. Cell proliferation was mea-
sured using the [3H]-thymidine incorporation rate as de-2308C one day and then thawed with 1 mL H2O at ambi-
ent temperature containing 1 mg Ap8A as the internal scribed elsewhere [4].
To establish a cause–effect relationship between ApnAstandard. Perchloric acid was added (final concentration
0.6 mol/L), and the precipitated proteins were removed and the growth of VSMCs, we first checked the ability to
increase the proliferative effect of supernatants of plate-by centrifugation at 2500 3 g for five minutes. The super-
natant was neutralized with KOH to precipitate KClO4. lets from healthy subjects and from hemodialysis patients
by the addition of exogenous ApnA (1025 mol/L).KClO4 was removed by centrifugation at 2500 3 g for
five minutes. Platelets were counted in a solution of resus- The putative agonists of supernatants of platelets from
healthy subjects and from hemodialysis patients werepended platelets directly after the sample was drawn.
blocked with the purinreceptor agonist pyridoxal-phos-
Incubation experiments with human platelets phate-6-azophenyl-2,4-disulfonic acid (PPADS;1026 mol/L).
Supernatants of thrombin-activated platelets from he-
Quantitation of ApnAmodialysis patients and healthy control subjects were
simultaneously incubated with 59-nucleotide hydrolase Ammonium acetate was added to the sample (final con-
centration 1 mol/L), and pH was adjusted to 9.5. There-(3 mU; from Crotalus durissus, EC 3.1.15.1 (Boehringer
Mannheim, Mannheim, Germany), purified according to after, the sample was passed through a boronate gel
(derivative of a cation exchange gel, BioRex 70; BioRad,Sulkowski and Laskowski) [7], and with alkaline phos-
phatase (1 mU; EC 3.1.3.1, from calf intestinal mucosa; Munich, Germany; column, 10 3 100 mm), which was
prepared according to Barnes et al [8]. The column wasBoehringer Mannheim) for two hours at 378C. The reac-
tion was terminated by an ultrafiltration with a centrifuge washed with 1 mol/l NH4Ac (pH 9.5) with a flow rate of
2 mL/min. The ApnAs were eluted with 10 mmol/L HClfilter (exclusion limit 10 kD).
Platelets from healthy control subjects were incubated in water (flow rate of 2 mL/min).
The eluate of the affinity chromatography was concen-with serum of hemodialysis patients before and after
hemodialysis for 90 minutes, stimulated with thrombin trated by HPLC reversed-phase C18 chromatography.
One mol/L TEAA in water was added to the eluate of(0.05 U/mL), and deproteinated with perchloric acid. The
precipitated proteins were removed by centrifugation at the affinity chromatography to a final concentration of
40 mmol/L. The reversed-phase column (Supersphere,2500 3 g for five minutes. The supernatant was neutral-
ized with KOH to precipitate KClO4. KClO4 was removed 250 3 4 mm; Merck) was equilibrated with 40 mmol/L
TEAA. The sample was pumped with a flow rate of 0.5by centrifugation at 2500 3 g for 5 minutes; 1 mol/L
triethylammonium acetate (TEAA) in water was added mL/min onto the column. After washing the column with
15 mL 40 mmol/L TEAA in water, ApnAs were elutedto the eluate of the affinity chromatography to a final
concentration of 40 mmol/L. The reversed-phase column with 35% acetonitrile in water. The eluate was collected
from the beginning of the increase in ultraviolet absorp-(Supersphere, 250 3 4 mm; Merck) was equilibrated
with 40 mmol/L TEAA. The sample was pumped with tion measured at a wavelength of 254 nm. The resulting
fractions were lyophilized and stored at 2308C.a flow rate of 0.5 mL/min onto the column. After washing
the column with 15 mL 40 mmol/L TEAA in water, To quantitate the amount of ApnA, the eluate of the
reversed-phase chromatography was chromatographedadsorbed substances were eluted with 35% acetonitrile
in water. The eluate was collected from the beginning by a reversed-phase column (Poros R 2/H, 100 3 2.1 mm;
Perseptive Biosystems, Cambridge, MA, USA). Eluentsof the increase in ultraviolet absorption measured at a
wavelength of 254 nm. The lyophilized eluate was added A and B used for the gradient elution were 2 mmol/L
tetrabutylammonium hydrogen sulfate in a phosphateto VSMCs.
buffer (10 mmol/L K2HPO4, pH 6.8) and water acetoni-
Cell proliferation assay trile (20:80, vol/vol), respectively. The mobile phase was
pumped at a flow rate of 300 mL/min. The ApnAs wereAortic smooth muscle cells from normotensive Wistar-
Kyoto rats were subcultured in 96-well dishes (Falcon, eluted by the following gradient: 0 to 1 minute, 100%
eluent A; 1 to 30.5 minutes, 0 to 30% eluent B; 30.5 toLincoln Park, NJ, USA) at a density of 5 3 104 cells/mL
and kept in culture medium containing 10% fetal calf 31.5 minutes, 30 to 50% eluent B. Ultraviolet absorption
was measured at 254 nm. Data were recorded and pro-serum (FCS) to reach a subconfluent monolayer. After
24 hours, the cells were growth arrested in 0.1% FCS cessed by an integrator (Merck).
for 48 hours without affecting cell adherence to culture
Identification of ApnAwells or viability as checked by trypan blue vital dye
exclusion. Quiescent VSMCs were then exposed to fresh For identification of the individual ApnA in the re-
versed-phase chromatogram, peak-fractionated lyophi-culture medium with 0.1% FCS with half of volume of
the supernatant of platelets activated by thrombin for a lized eluate of the reversed-phase chromatography was
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dissolved in 100 mL 20 mmol/L K2HPO4 (pH 8) and sub-
jected to an anion exchange column (MiniQ PC 1.6/5;
Pharmacia, Uppsala, Sweden; equilibration and sam-
ple buffer, 20 mmol/L K2HPO4, pH 8, flow rate of 100
mL/min). Retained substances were eluted by 1 mol/L
NaCl in 20 mmol/L K2HPO4 in water; 1 mol/L TEAA
in water was added to the eluate of the anion-exchange
chromatography to a final concentration of 40 mmol/L.
The mixture was loaded to a reversed-phase column
(Supersphere RP-C18, 2.1 3 100 mm; Merck; equilibra-
tion and sample buffer, 40 mmol/L TEAA in water;
flow rate of 100 mL/min). ApnAs were eluted by 20%
acetonitrile in water.
The lyophilized fractions from the reversed-phase chro-
matography were examined by matrix-assisted laser de- Fig. 1. [3H]-thymidine incorporation of vascular smooth muscle cells
(VSMCs) stimulated by the supernatant of 106-stimulated platelets fromsorption/ionization mass spectrometry (MALDI-MS) as
hemodialysis patients and healthy control subjects in the absence (h)well as postsource decay (PSD)-MALDI-MS. A reflec-
and presence (j) of the selective P2-receptor blocker, PPADS. Ordinate:
tron type time-of-flight (RETOF) mass spectrometer in counts/supernatant of 106-stimulated platelets. Data are means 6
SEM (P , 0.05 compared with control).(Reflex III; Bruker, Rheimstetten, Germany) was used
according to Hillenkamp and Karas [9]. The sample was
mounted on an x, y, z movable stage allowing irradiation
of selected sample areas. In this study, a nitrogen laser
midine incorporation in VSMCs was about 65.9% higher(VSL-337 NDl Laser Science) with an emission wave-
than that of the supernatant of healthy control subjectslength of 337 nm and a 3 ns pulse duration was used.
(N 5 17, 604 6 71 vs. 364 6 45 counts/supernatant ofThe laser beam was focused to a diameter of 50 mm at
106 stimulated platelets 6 SEM; P , 0.05; Fig. 1).an angle of 458 to the surface of a target. Microscopic
The addition of the selective P2-receptor blockersample observation was possible. Ten to 20 single spectra
PPADS to the supernatants of thrombin-activated plate-were accumulated for a better signal-to-noise ratio. In
lets from hemodialysis patients and healthy control sub-MALDI-MS large fractions of the desorbed analyte ions
jects significantly inhibited the stimulatory effects ofundergo PSD during flight in the field free drift path.
ApnA on the growth of vascular smooth cells (219 6 53Using a RETOF setup, sequence information from PSD
vs. 156 6 71 counts/supernatant of 106 stimulated plate-fragment ions of precursors produced by MALDI was
lets 6 SEM).obtained [10]. The sample preparation for the MALDI-
After simultaneous incubation of supernatants of throm-and PSD-MALDI experiments was identical. The con-
centrations of the analyzed substances were 1 to 10 bin-activated platelets from hemodialysis patients and
mmol/L in double-distilled water. One microliter of the healthy control subjects with 59-nucleotide hydrolase and
analyte solution was mixed with 1 mL of the matrix solu- alkaline phosphatase, the growth-stimulating effect of the
tion (50 mg/mL 3-hydroxy-picolinic acid in water). To supernatants significantly decreased (462 6 13 vs. 260 6 18
this mixture, cation exchange beads (AG 50 W-X12, counts/supernatant of 106 stimulated platelets 6 SEM).
200 to 400 mesh; Bio-Rad) equilibrated with NH41 as a Which factors in the platelet supernatant are responsi-
counter ion were added to remove Na1 and K1 ions. ble for the increased [3H]-thymidine incorporation rate
The mixture was gently dried on an inert metal surface in hemodialysis patients? Chromatograms from platelet
before introduction into the mass spectrometer. The supernatants of hemodialysis patients show increased
mass accuracy was in the range of approximately 0.01%. amounts of nucleotides, as evidenced by increased ultra-
violet absorbance peaks at 254 nm compared with thoseStatistics
of healthy controls. Representative chromatograms from
Results are presented as the means 6 SEM. Where hemodialysis patients and healthy subjects are shown in
error bars do not appear in the figures, errors are within Figure 2. Furthermore, several of those nucleotides were
the symbol size. Statistical analyses were performed with
identifiable by their retention times and by MALDI and
the Wilcoxon–Mann–Whitney test or with the Kruskal–
MALDI-PSD mass spectrometry. Figure 3 shows theWallis test for multiple comparisons.
MALDI-PSD spectrum of the peak labeled in Figure 2
as Ap4A. The molecular mass of the substance was deter-
RESULTS mined as 836.4 (837.4 5 [M 1 H]1) D. This molecular
mass, as well as the fragments, corresponds to that ofThe effect of the supernatant of thrombin-activated
platelets from hemodialysis patients (N 5 15) on [3H]-thy- authentic Ap4A. Similarly, other ApnA with three, five,
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phy. The amount of any of the ApnA was significantly
higher in supernatant of platelets from hemodialysis pa-
tients compared with healthy control subjects (Ap3A,
119 6 32 vs. 12 6 3; Ap4A, 154 6 59 vs. 43 6 20; Ap5A,
39 6 14 vs. 13 6 6; Ap6A, 42 6 19 vs. 2 6 1 fg/platelet;
each P , 0.05, N 5 10).
Next, the intracellular content of ApnA in intact plate-
lets from hemodialysis patients was compared with that
in healthy controls by the HPLC quantitation method.
Figure 4 shows a typical chromatogram of a homogenate
from human platelets. The ApnAs were identified by
their retention times and their molecular masses, as re-
vealed by MALDI-MS. As shown in Figure 5, the
amounts of ApnA in intact platelets from hemodialysis
patients (N 5 61) was significantly increased compared
with those of healthy controls (N 5 30, Ap3A, 366 6 68
vs. 15 6 1; Ap4A, 336 6 48 vs. 19 6 2; Ap5A, 227 6 35
vs. 10 6 1; Ap6A, 141 6 45 vs. 4 6 1 fg/platelet, each
P , 0.01).
A percentage (91.8%) of the patients had cardiovascu-
lar disease, whereas 8.2% had no cardiovascular disease.
ApnAs in platelets from patients with and without cardio-
vascular disease were as follows: Ap3A, 385 6 74 vs.
157 6 56; Ap4A, 353 6 52 vs. 149 6 40; Ap5A, 238 6
58 vs. 99 6 47; Ap6A, 146 6 49 vs. 83 6 28 fg/platelet 6
SEM, showing no significant differences between the
two groups.
Platelets from patients with chronic renal failure (N 5Fig. 2. Reversed-phase chromatography of supernatant of platelets ac-
5) before entering hemodialysis also contained elevatedtivated by thrombin from hemodialysis patients (A) and healthy control
subjects (B) on an analytical reversed-phase, high-pressure liquid chro- concentrations of ApnA compared with healthy control
matography (HPLC) column. subjects (Ap3A, 657 6 263 vs. 15 6 1; Ap4A, 826 6 411
vs. 19 6 2; Ap5A, 310 6 102 vs. 10 6 1; Ap6A, 71 6 31
vs. 4 6 1 fg/platelet 6 SEM).
or six phosphate groups (Ap3A, Ap5A, Ap6A) were
shown to underlie those ultraviolet peaks, which were
DISCUSSIONmarkedly increased in platelet supernatants from hemo-
Platelets from hemodialysis patients contain markedlydialysis patients.
elevated amounts of ApnA. Obviously, the increasedThe addition of exogenous ApnA (1025 mol/L) to su-
ability of supernatants from aggregated platelets to in-pernatants of thrombin-activated platelets from hemodi-
duce VSMC growth is at least partly due to an increasedalysis patients and healthy control subjects increased the
content of ApnA and an increased release by aggrega-growth of vascular smooth cells [(counts/supernatant of
tion. The growth-stimulating effect of the supernatants106 stimulated platelets 6 SEM) hemodialysis patients:
of thrombin-activated platelets on cultured VSMCs wasAp3A, 697 6 55; Ap4A, 725 6 53; Ap5A, 703 6 31; Ap6A,
partly abolished by the selective P2-receptor blocker739 6 51, and healthy control subjects: Ap3A, 438 6 21;
PPADS as well as enzymatic cleavage of ApnA.Ap4A, 461 6 32; Ap5A, 499 6 19; Ap6A, 463 6 31].
Earlier platelet studies showed that thrombin concen-Supernatants of thrombin-activated platelets from
trations of 0.05 U/mL caused maximum activation ofhealthy control subjects after incubation with uremic
platelets [11]. Thrombin remaining in the supernatantserum of hemodialysis patients before and after hemodi-
after platelet aggregation is not responsible for thealysis increased the growth of VSMCs to a similar extent
growth-stimulating effect since the supernatants were(356 6 54 vs. 382 6 65 counts/supernatant of 106 stimu-
deproteinated with perchloric acid prior to applicationlated platelets).
to VSMCs. In addition, the addition of similar concentra-Since an increased release of the potent VSMC growth
tions of the authentic Ap3A, Ap4A, Ap5A, and Ap6Afactors, ApnAs [4], was seen after aggregation of platelets
(that had never been exposed to thrombin) increasedof hemodialysis patients, the amounts released after
platelet aggregation were quantitated by chromatogra- the growth of VSMCs to the same extent. Exogenous
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Fig. 3. Characteristic positive-ion post-source
decay (PSD) matrix-assisted laser desorption/
ionization mass spectrometry (MALDI-MS)
mass spectrum of a fraction of reversed-phase
chromatography. The underlying substance
was identified as Ap4A. Abbreviations are: A9,
adenine; A, adenosine; M, protonated parent
ion; p, phosphate group (for example, Ap2
adenosine diphosphate). Abscissa is the rela-
tive mass/charge, m/z, z 5 1; the ordinate de-
notes relative intensity in arbitrary units.
it is known that Ap5A and Ap6A concentrations above
1028 mol/L are sufficient to stimulate VSMC prolifera-
tion. In hemodialysis patients, 105 platelets may release
approximately 4 3 10215 mol Ap5A. In 1 mL, an extracel-
lular concentration of 4 3 1029 mol/L would result. This
estimation is based on a platelet count of 105/mL in whole
blood. However, after formation of a platelet thrombus,
even higher local concentrations of Ap5A may be
reached. The findings suggest that an increased ApnA
content in platelets may contribute to VSMC growth and
hence to premature atherosclerosis in end-stage renal
failure. This may be an additional important mechanism
that induces vascular damage and hence increases mor-
bidity in end-stage renal failure. Compared with plateletsFig. 4. Reversed-phase chromatography of homogenate of human
from healthy donors, the accumulation of Ap6A is mostplatelets after affinity- and reversed-phase chromatography (conditions
as described in Fig. 2). Ap8A was added to the sample as an internal prominent.
standard. How can the increased amount of ApnA in platelets
from hemodialysis patients be explained? Principally,
either an increased production or a decreased break-
down has to be considered. Dinucleoside polyphosphatesApnA increased this growth-stimulating effect. The
are degraded by asymmetrical and symmetrical hy-growth-stimulating effect of ApnA has been described
drolases and phosphorylases; for example, Ap3A is splitby Heidenreich et al [4]. The effect of platelets from
to AMP and ADP by an enzyme characterized as glyco-healthy control subjects is not affected by the incubation
protein complex with 5-nucleotide phosphodiesterase ac-with uremic serum.
tivity [12]. Furthermore, ApnAs are degraded by phos-The results revealed that intact platelets of hemodialy-
phodiesterases, which have a broad substrate specificitysis patients contain increased amounts of ApnA and re-
[13]. The activity of dinucleoside polyphosphate-degrad-lease increased amounts upon aggregation. The platelet
ing enzymes might be inhibited in end-stage renal failurecount was significantly higher in hemodialysis patients
by metabolites accumulating in the organism in spitecompared with healthy control subjects. However, the
of regular dialysis. The inhibition of these enzymes byconcentrations of ApnA were given in fg per platelet,
uremic toxins could perhaps result in increasing concen-indicating an increased content of ApnA per platelet
trations of dinucleoside polyphosphates with end-stagefrom hemodialysis patients. These amounts are sufficient
to stimulate local cell growth. From earlier experiments, renal failure.
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Fig. 5. Intracellular concentrations of the Ap3A,
Ap4A, Ap5A, and Ap6A in platelets from hemo-
dialysis patients. Data are means 6 SEM (P ,
0.01 compared with control).
Di Minno et al showed that platelet dysfunction in ure- sclerosis in dialysis. VSMC proliferation is just one of
the players in a complex, multicellular process.mia is partially corrected by dialysis [14]. The incubation
experiments with platelets from healthy subjects and ure- In conclusion, the increased amount of ApnA in intact
platelets from hemodialysis patients probably entail anmic serum before and after hemodialysis, respectively,
showed no significant change in the growth-stimulatory increased proliferation of VSMCs, and as a result, the
risk of arteriosclerotic diseases of hemodialysis patientspotency of the supernatant after platelet aggregation.
These findings can be reconciled with the results ob- increases.
tained with supernatants from uremic platelets, assuming
that either the incubation of healthy platelets with ure- ACKNOWLEDGMENTS
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